Boehringer Ingelheim earns USFDA approval for Jascayd tablets for progressive pulmonary fibrosis
Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults. This represents a…